YOLFTbeta
Quoin Pharmaceuticals Ltd DRC

Quoin Pharmaceuticals Ltd DRC

QNRX · NASDAQ · Healthcare / Biotechnology

3.70USD-0.05 (-1.33%)

Price History

Full chart

Market Stats

Previous Close3.75
Open3.99
Day Range3.55 – 3.99
52-Week Range3.25 – 23.50
Volume16.03K
Market Cap12.91M
P/E (TTM)0.00
Forward P/E0.00
EPS-5.67
Dividend Yield0.00%
Beta1.73
50-Day Avg5.61
200-Day Avg7.13

About

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Michael Myers Ph.D.
  • Employees4
  • Headquarters42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349, USA
  • Websitehttps://quoinpharma.com

Leadership

  • Dr. Michael Myers Ph.D.Co-Founder, CEO & Chairman · b. 1962
  • Ms. Denise CarterCo-Founder, COO & Director · b. 1969
  • Ms. Sally LawlorChief Financial Officer · b. 1983

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--280.00K--280.00K0000000
Growth (%)----+100.00%------
Cost of Revenue18.27K89.13K104.22K125.72K227.06K104.77K104.11K103.64K103.44K100.47K100.79K
Gross Profit-18.27K-280.00K-104.22K-280.00K-227.06K-104.77K-104.11K-103.64K-103.44K-100.47K-100.79K
Gross Margin-100.00%-100.00%-------
Operating Expense2.58M-15.60M-10.28M-15.60M1.33M1.57M5.96M9.15M9.28M9.43M16.19M
Operating Income-2.60M15.32M10.17M15.32M-1.56M-1.67M-6.06M-9.26M-9.38M-9.53M-16.29M
Operating Margin--5470.36%--5470.36%-------
EBITDA-2.60M15.32M10.17M15.32M-1.54M-1.57M-20.27M-8.56M-8.58M-8.86M-15.70M
EBITDA Margin--5470.36%--5470.36%-------
Net Income-2.62M15.32M10.17M15.32M-1.56M-2.10M-21.46M-9.38M-8.69M-8.96M-15.80M
Net Income Margin--5470.36%--5470.36%-------
R&D1.52M8.26M5.89M8.26M45.65K244.16K1.56M2.67M3.31M3.60M9.80M
R&D as % of Total Revenue--2948.57%--2948.57%-------
Interest Expense----412.29K1.19M1.09M714.08K0--

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.43M8.81M8.75M5.52M6.17M1.38M9.36M14.46M12.17M15.71M20.39M
Total Liabilities735.02K1.41M3.32M1.80M1.88M7.99M8.70M7.05M6.51M6.50M7.27M
Total Equity2.70M7.40M5.43M3.73M4.30M-6.61M657.03K7.41M5.66M9.20M13.12M
Cash1.01M1.63M3.96M4.77M5.24M323.83K7.48M2.86M2.40M3.62M3.82B
Total Debt-15.07K--310.65K1.21M-----
Net Debt-1.01M-1.62M-3.96M-4.77M-4.93M889.48K-7.48M-2.86M-2.40M-3.62M-3.82B

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.98M-3.77M-4.98M-6.57M-5.71M-1.34M-5.72M-8.48M-7.86M-7.86M-13.54M
Investing Cash Flow817.09K-4.71M2.83M3.81M-30.31K-125.00K-625.00K-10.15M2.19M-1.89M-4.28M
Financing Cash Flow1.65M9.13M4.43M3.55M6.14M1.79M13.50M14.01M5.22M10.97M18.01M
Capital Expenditure85.44K330.64K74.53K182.46K34.52K125.00K625.00K250.00K3.7704
Free Cash Flow-2.07M-4.10M-5.05M-6.76M-5.74M-1.46M-6.35M-8.73M-7.86M-7.86M-13.54M
Dividends Paid-------65.27M---
FCF to OCF104.31%108.78%101.50%102.78%100.60%109.34%110.93%102.95%100.00%100.00%100.00%
Dividend Paid to FCF--------747.54%---

Earnings

Report DateSep 1, 2016Nov 28, 2016Mar 23, 2017May 29, 2017Aug 21, 2017Nov 22, 2017Mar 19, 2018May 17, 2018Aug 9, 2018Nov 13, 2018Mar 18, 2019May 21, 2019Aug 13, 2019Nov 19, 2019Mar 31, 2020Apr 3, 2020Aug 12, 2020Nov 20, 2020Mar 29, 2021Jun 16, 2021Aug 24, 2021Dec 20, 2021Mar 21, 2022Apr 14, 2022Aug 18, 2022Nov 10, 2022Mar 8, 2023May 9, 2023Aug 3, 2023Nov 9, 2023Mar 13, 2024May 9, 2024Aug 8, 2024Nov 8, 2024Mar 11, 2025May 13, 2025Aug 7, 2025Nov 6, 2025Mar 26, 2026Mar 31, 2026Aug 14, 2026Nov 5, 2026
EPS Estimate---50.00-55.00-55.00-75.00-77.50-75.00-72.50-70.000.000.000.000.000.000.000.000.000.000.00--1365.00-0.73-4392.51-1158.15-495.60-0.62-96.60-96.60-95.32-2.31-14.35-20.30-0.40-0.43-4.20-6.83-1.92-4.02-2.26-1.83-1.88
EPS Actual-4.10-6.00-17.50-14.80-3.20-98.00-40.00-40.00-62.50-72.50-3.17-0.41-2.47-3.14-0.89-0.01-0.04-0.01-0.04-1.75-0.18-7402.51-309.0022207.53-1360.80-395.26-0.41-144.10-73.48-68.25-2.08-38.62-13.67-16.51-0.28-6.50-6.28-6.70-1.74-1.77-1.90-
Surprise--65.00%73.09%94.18%-30.67%48.39%46.67%13.79%-3.57%------------442.31%-41940.82%605.58%-17.50%20.25%33.87%-49.17%23.93%28.40%9.96%-169.13%32.66%-4027.50%35.33%-54.76%8.05%-248.96%56.72%21.68%-3.83%-
TimingPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-market-Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap12.91M
Enterprise Value2.76M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.45
EPS-5.67
Book Value8.76
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-19.05M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-575.73%
Return on Assets-114.60%
Shares Outstanding2.01M
Shares Float1.93M
Beta1.73
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 21.83
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
66.39%
Insiders
8.77%
Retail / Other
24.84%

Top Institutional Holders

  • Ikarian Capital, LLC
    211.54K10.53%
  • Dauntless Investment Group, LLC
    196.59K9.79%
  • Millennium Management LLC
    112.32K5.59%
  • SummitTX Capital, L.P
    100.30K4.99%
  • Woodline Partners LP
    79.58K3.96%
  • Aberdeen Group PLC
    75.00K3.73%
  • Soleus Capital Management, L.P.
    72.73K3.62%
  • AIGH Capital Management, LLC
    70.00K3.49%
  • Centiva Capital LP
    60.00K2.99%
  • BOOTHBAY FUND MANAGEMENT, LLC
    59.84K2.98%
  • Stonepine Capital Management Llc
    53.46K2.66%
  • Velan Capital Investment Management LP
    32.37K1.61%
  • Birchview Capital, LP
    20.00K1.00%
  • Morgan Stanley - Brokerage Accounts
    4.00K0.20%
  • UBS Group AG
    2.51K0.13%
  • Rhumbline Advisers
    1.52K0.08%
  • Barclays PLC
    1.30K0.06%

Top Fund Holders

  • abrdn World Healthcare
    40.40K2.70%
  • abrdn Life Sciences Investors
    34.60K2.31%
  • Abante Quant Value FI
    10.48K0.70%

Stock Splits

  • Apr 9, 20251:35
  • Jul 18, 20231:12
  • Aug 1, 20228:100
  • Sep 24, 20211:4
  • Oct 23, 20191:5